Anixa Biosciences Inc (NASDAQ:ANIX – Get Free Report) CEO Amit Kumar purchased 5,000 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was purchased at an average price of $2.76 per share, for a total transaction of $13,800.00. Following the transaction, the chief executive officer directly owned 662,000 shares in the company, valued at approximately $1,827,120. This trade represents a 0.76% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Amit Kumar also recently made the following trade(s):
- On Friday, July 31st, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.47 per share, with a total value of $17,350.00.
- On Friday, July 24th, Amit Kumar bought 3,000 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $3.73 per share, with a total value of $11,190.00.
- On Monday, July 20th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.46 per share, for a total transaction of $17,300.00.
- On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $3.37 per share, for a total transaction of $10,743.56.
- On Monday, July 27th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $3.44 per share, with a total value of $17,200.00.
- On Friday, July 10th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $3.04 per share, with a total value of $15,200.00.
Anixa Biosciences Stock Performance
ANIX stock opened at $2.76 on Monday. The firm has a market cap of $95.94 million, a PE ratio of -8.62 and a beta of 0.51. The stock has a 50-day moving average price of $3.33 and a 200-day moving average price of $2.98. Anixa Biosciences Inc has a 1-year low of $2.32 and a 1-year high of $5.46.
Institutional Trading of Anixa Biosciences
A number of institutional investors have recently modified their holdings of ANIX. Sanctuary Advisors LLC purchased a new position in Anixa Biosciences in the 2nd quarter valued at approximately $29,000. Northwestern Mutual Wealth Management Co. bought a new stake in Anixa Biosciences during the 2nd quarter worth approximately $29,000. Integrated Wealth Concepts LLC purchased a new stake in Anixa Biosciences in the 2nd quarter worth approximately $30,000. NewEdge Advisors LLC purchased a new position in shares of Anixa Biosciences during the 2nd quarter valued at $33,000. Finally, Simplicity Wealth LLC bought a new position in shares of Anixa Biosciences in the second quarter worth $34,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research firms have recently commented on ANIX. Weiss Ratings downgraded Anixa Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, June 30th. HC Wainwright restated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Zacks Research lowered Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $10.00.
Read Our Latest Research Report on ANIX
Anixa Biosciences Company Profile
Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.
See Also
- Five stocks we like better than Anixa Biosciences
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
